<p><i><strong>Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable disease</strong></i></p><p><i><strong>Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months</strong></i></p><p><i><strong>Biomarker analysis confirms immune activation in the tumor microenvironment</strong></i></p><p><i><strong>Data Presented at Society for Immunotherapy of Cancer on November 8, 2024</strong></i></p>

The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.

HanchorBio Received IND Approval of HCB101 Multi-Regional Clinical Trial By Taiwan FDA

HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA

Bringing industry and academia together to discuss the potential impact of single-cell analytics powered by machine learning for precision medicine.

Webinar on the latest developments in the analysis of single-cell data, including from transcriptomic and imaging technologies.

A PNAS study demonstrates platelet-derived growth factor D (PDGF-D) binding to PDGF receptor-beta (PDGFRβ) activates NK cells to enhance interleukin (IL)-15-mediated NK cell survival.
City of Hope research suggests that the selective introduction of PDGF signaling in NK cells by IL-15 should benefit NK cell expansion and persistence and/or enhance effector function in NK cell-based immunotherapies.

First closing of Series A round and onboarding of top biotech leaders to fuel growth in 2022

Proceeds from this financing will support the development of the Company's proprietary platform, which leverages the inherent capacity of NK cells to distinguish between normal and diseased tissues.

Webinar on Monday, July 26 at 10 am ET

With an experienced Chief Financial Officer on board, the company is continuing to advance its fight against cancer.

(i) Study shows Philogen's proprietary immunocytokines are effective treatment for brain tumors.
(ii) Early promising findings from Philogen's Phase I/II study investigating the safety and efficacy of L19TNF monotherapy in patients with glioblastoma.
(iii) Philogen's proprietary cancer treatment found to be safe and well-tolerated.

APCEDEN®, APAC's immunotherapy product, has already been approved by the Indian FDA for treating cancer. The company has further announced it will conduct clinical trials for highly aggressive brain tumors (GBM) and pancreatic cancers (PDAC) with its new technology.

The universal vaccine is designed to protect elderly adults from all respiratory viral infections, including COVID-19, influenza and any future mutations or novel viral outbreaks.

Dr. Gaines of Life Gaines Medical & Aesthetics Center sends out info about the COVID-19 virus for concerned patients and the general public in South Florida

Company founder Robert Coates becomes Executive Chairman

Will Be Honoring Leaders in Immunotherapy (Carl June, U Penn), CRISPR Technology (Feng Zhang, Broad Institute), Pharma (George D. Yancopoulos, Regeneron Pharmaceuticals) and Patient Research Advocacy (Sharon Terry, Genetic Alliance)

Researchers will use IASLC/LCFA funds to create new lung cancer treatments for never-smokers and patients whose cancer has spread

Gladstone researchers have stopped the detrimental effects of blood-brain barrier leaks

Structured Immunity to evaluate specificity and recognition properties of a lead T cell receptor using structural immunology platform

PD-L1 expression measured by immunohistochemistry helps identify non-small cell lung cancer (NSCLC) patients that may respond to anti-PD-1/PD-L1 immunotherapies.

One of America's foremost oncologists leads this webinar series on the past, the present and the future of immunotherapy studies

Highlands Oncology Group Will Collaborate To Research Immunotherapy For Ovarian Cancer

Local Oncologist Published Research In Medical Journal The Lancet Oncology

Live Like Bella® founded in 2013 has approved a grant to Aurora Biopharma to admit children for the first time into their cutting-edge Immunotherapy research. This is incredible news for the Cancer Community and especially children suffering with the very deadly forms of cancer known as Glioblastoma (Brain Cancer) and Osteocracoma (Bone Cancer) .

Immunotherapy made a giant leap forward this weekend with the release of clinical trial results of BMS's ipilimumab. The results indicate that ipilimumab significantly improved the survival of patients with late stage melanoma.